Entering text into the input field will update the search result below

Reata Pharma hit by setback in FDA review of FA treatment

Nov. 24, 2020 6:35 PM ETReata Pharmaceuticals, Inc. (RETA) StockRETABy: Carl Surran, SA News Editor2 Comments
  • Reata Pharmaceuticals (NASDAQ:RETA) -8.8% after-hours following news that the Food and Drug Administration's review of its proposed omaveloxolone treatment for Friedreich's ataxia, a rare neuromuscular disorder, concluded that the findings do not strengthen the results of Part 2 of

Recommended For You

Related Stocks

SymbolLast Price% Chg
RETA--
Reata Pharmaceuticals, Inc.